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Abstract. Granulocytic sarcoma (GS) is a rare extramedul-
lary manifestation of acute myeloid leukemia (AML). GS may 
develop simultaneously to AML or as a relapse of leukemia, 
particularly following allogeneic hematopoietic stem cell trans-
plant. Subperiosteal bone, lymph nodes and skin are commonly 
involved, whereas rhinopharyngeal involvement is less common, 
with only 14 cases reported in the literature. Due to its rarity, 
rhinopharyngeal GS may lead to diagnostic pitfalls, particu-
larly when it is poorly differentiated or is without concomitant 
marrow involvement. Thus, immunohistochemical findings play 
a key role in diagnosis. The current report describes a case of a 
53-year-old female suffering from rhinopharyngeal GS and with 
a history of AML treated with chemotherapy and radiotherapy, 
focusing on the importance of the immunohistochemical pattern 
to assess the right diagnosis. Recent studies have demonstrated 
that the immunophenotype is of utmost importance for the diag-
nosis of GS. The high expression of myeloperoxidase (MPO) is 
common in GS; however, ~30% of GSs do not contain MPO. 
Therefore, the presence of other markers is required to confirm 
the diagnosis of GS.
Introduction
Granulocytic sarcoma (GS) is a rare, extramedullary malig-
nant neoplasm consisting of myeloid cells with different levels 
of maturation and occurring in anatomic sites other than the 
bone marrow or peripheral blood (1). It represents a distinct 
entity of AML (2).
The high expression of myeloperoxidase (MPO) makes 
these tumors green, hence their alternative name, ‘chloroma’ 
(from the Greek word ‘chloros’, meaning green). However, 
‘sarcoma’ is the most commonly used term, as ~30% of 
these tumors do not contain MPO, despite the fact that MPO 
together with cluster of differentiation (CD)117 represents the 
marker for myeloid differentiation (1).
GS may develop de novo (solitary, primary or non-leukemic 
GS; 8-20%) (3), simultaneously to AML (2.5-9.1%) (4), or as a 
relapse of leukemia, particularly following allogeneic hema-
topoietic stem cell transplant (AHSCT) (4,5). The reason for 
this association is still unknown, but may be attributed to a 
pattern of graft-versus-leukemia surveillance or to the biology 
of high-risk AML treated with transplantation (5).
 GS may affect patients of all ages (median age, 56 years; 
range, 1 month to 89 years), with a male:female ratio 1.2:1 (6). 
Commonly involved sites include subperiosteal bone, lymph 
nodes and skin. The prevalence of head and neck region 
involvement is 12-43% of cases (5), and orbit, skull and 
epidural spaces are the most frequently involved sites (7). Rare 
lesions have been described in the maxilla, soft palate, para-
nasal sinus, salivary gland, scalp and temporal bone, whereas 
only a few cases have been described with rhinopharyngeal 
involvement (4).
GS risk factors include specific chromosomal abnormali-
ties [t(8;21) and inv(16)], expression of cell-surface markers 
(CD56, CD2, CD4 and CD7), and M2, M4 and M5 leukemia 
subtypes of the French-American-British classification (4). 
Additional risk factors include poor nutritional status, cellular 
immune dysfunction, high presenting leukocyte count and 
decreased blast Auer rods (4).
Sinonasal congestion and/or hearing loss are the most 
common clinical manifestations of rhinopharyngeal GS (4).
The diagnosis of the rhinopharyngeal GS, particularly 
when it is poorly differentiated or without concomitant marrow 
involvement, is challenging (8), and it is not uncommon for 
GS to be misdiagnosed as lymphoma (8,9). To improve the 
accuracy of diagnosis, immunohistochemical patterns play a 
key role. For instance, myeloid cells are reactive to antibodies 
against lysozyme, MPO and chloroacetate esterase. Further-
more, GS myeloblasts typically express myeloid-associated 
antigens, such as CD43, but are not reactive to lymphoid anti-
gens. In addition, flow cytometry and cytogenetic analysis may 
aid in determining a definitive diagnosis (8).
GS is sensitive to focal irradiation and to systemic chemo-
therapy, similarly to AML (7,10,11). Systemic treatment should 
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always be considered due to the high rate of recurrence and 
progression to AML (11). Surgery may be a therapeutic option 
only for tumors, which cause organ dysfunction (11). The 
role of radiotherapy and AHSCT as a consolidation regimen 
remains to be clearly established (10,11).
GS has an unfavorable prognosis. Its course is rapid with a 
high mortality rate, particularly when associated with AML, 
whereas patients without evidence of leukemia have a better 
prognosis (9); cases initially diagnosed as solitary GS without 
evidence of leukemia and treated with systemic chemotherapy 
have a more favorable prognosis (9).
The current study reports the case of a 53-year-old woman 
who presented with a rhinopharyngeal mass. The mass was 
diagnosed as an isolated extramedullary GS as a relapse of 
AML, which had been treated 7 years earlier with chemo-
therapy and AHSCT and was followed by complete remission. 
In addition, a review of the literature is reported, along with 
the examination of immunohistochemical features as a tool for 
the differential diagnosis of GS compared to other rare tumors 
of the rhinopharynx.
Case report
A 53-year-old female non-smoker presented to the Ear, Nose 
and Throat Unit of ‘Federico II’ University of Naples (Naples, 
Italy) complaining of left otalgy, hearing loss and nasal 
obstruction for ~5 months. The patient had a history of AML, 
which was in complete remission following high-dose chemo-
therapy and AHSCT, administered 7 years earlier.
A nasal endoscopy revealed a left rhinopharyngeal 
peritubaric mass obstructing the left Eustachian tube. The 
audiological evaluation revealed left conductive hearing loss 
due to an ipsilateral middle ear effusion. No lateral cervical 
palpable lymph nodes were found. Magnetic resonance imaging 
and positron emission tomography-computed tomography (CT) 
examinations revealed a mass of the rhinopharynx (6x3.5 cm; 
standardized uptake value, 5.7) without bone erosion.
Laboratory studies, including a normal complete blood 
count, unremarkable serum chemistry and normal liver 
enzyme levels, did not reveal any alteration. No evidence of 
increased blast cell count was observed in the bone marrow 
aspiration sample.
The specimen was formalin fixed and paraffin embedded. 
Immunohistochemistry was performed using the avidin biotin 
complex as a visualization system and 3,3'-diaminobenzidine 
as chromogen for the reaction, with pre-diluted antibodies 
(dilution, 1:100) against B-cell lymphoma-2 (Bcl-2; 790-4604, 
clone SP66; rabbit; Ventana Medical Systems, Inc., Tucson, 
AZ, USA), CD3 (790-4341; clone 2GV6; rabbit; Ventana 
Medical Systems, Inc.), CD5 (790-4451; clone SP19; rabbit; 
Ventana Medical Systems, Inc.), CD10 (790-4506; clone SP67; 
rabbit; Ventana Medical Systems, Inc.), CD20 (760-2531; clone 
L26; mouse; Ventana Medical Systems, Inc.), CD34 (790-
2927; clone QBEnd/10; mouse; Ventana Medical Systems, 
Inc.), CD43 (760-2511; clone L60; mouse; Ventana Medical 
Systems, Inc.), CD56 (790-4465; clone 123C3; mouse; Ventana 
Medical Systems, Inc.), CD99 (790-4452; clone O13; mouse; 
Ventana Medical Systems, Inc.), CD117 (790-2951; clone 9.7; 
rabbit; Ventana Medical Systems, Inc.), Ki67 (M724029; clone 
MIB1; mouse; Dako, Glostrup, Denmark) and MPO (760-
2659; rabbit polyclonal; Ventana Medical Systems, Inc.). The 
patient underwent biopsy of the rhinopharyngeal lesion, which 
revealed neoplastic proliferation of medium- and small-sized 
cells. These cells exhibited inconspicuous cytoplasm, nuclei 
with irregular membranes, occasionally a small nucleolus, 
diffuse karyorrhexis and high mitotic activity (Fig. 1).
Figure 1. Histopathological analysis of biopsy specimen. (A and B) The neoplastic cell population was composed of small and medium sized elements, 
characterized by an inconspicuous eosinophilic cytoplasm and a nucleus with an irregular nuclear membrane; occasionally a small nucleolus was observed 
[hematoxylin and eosin staining; magnification, (A) x20 and (B) x40]. (C) Neoplastic cells were strongly immunoreactive for cluster of differentiation 43. 
(D) A high proliferative index was observed (Ki-67, 40%).
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The immunohistochemical evaluation revealed strong 
reactivity for CD43, CD34 and CD99, whereas CD20, CD3, 
CD5, CD10, Bcl-2, MPO, CD117 and CD56 were all negative. 
The Ki-67 proliferative index was ~40%. Fluorescence in situ 
hybridization (FISH) analysis was performed on 4-µm-thick 
formalin‑fixed, paraffin‑embedded (FFPE) tissue sections, 
using the Vysis LSI Dual Color probe (Abbott Molecular, 
Inc., Des Plaines, IL, USA) specific for runt‑related transcrip-
tion factor 1 (RUNX1) labeled with Spectrum Green and for 
RUNX1T1 labeled with Spectrum Orange. The slides were 
hybridized overnight according to the manufacturer's protocol. 
Image analysis was then conducted. The FISH analysis of 
FFPE tumor slides did not identify either the t(8;21) transloca-
tion or MLL gene dissociation.
The patient's medical history and immunophenotype 
suggested the presence of a poorly differentiated extramedul-
lary GS of the rhinopharynx as a relapse of AML, without 
bone marrow disease.
The patient was treated with conventional induction AML 
therapy: Combined idarubicin (12 mg/m2/day, days 1-2) and 
cytarabine (200 mg/m2/day, days 1-7), followed by one course 
of consolidation therapy with idarubicin (12 mg/m2, day 1) and 
cytarabine (1 g/m2/12 h, days 1-5), as well as radiation treat-
ment (1,500 cGy in 5 fractions).
A CT scan performed at 1 month after chemoradiotherapy 
revealed complete resolution of the rhinopharyngeal mass. 
At the 3-year follow-up, the patient was asymptomatic and 
without signs of recurrence. At present, the patient is under a 
regular surveillance protocol; she is closely monitored through 
a multidisciplinary ‘short time’ follow-up protocol, consisting 
of nasal endoscopy and blood studies every 3 months.
Written informed consent was obtained from the patient for 
publication of this case report and the accompanying images.
Discussion
GS, also known as ‘chloroma’ or ‘extramedullary myeloblas-
toma’, is a rare solid tumor consisting of primitive precursors 
of the granulocytic series of white blood cells, which include 
myeloblasts, promyelocytes, and myelocytes (1). Rhinopharyn-
geal localization of GS is extremely rare; only a few cases have 
been previously reported in the literature (4), and the present 
study reports the 15th case (Table I).
GS has a high rate of misdiagnosis (46%) (12,13), and its 
differential diagnosis may include non-Hodgkin's lymphoma 
(lymphoblastic, Burkitt and diffuse large B-cell lymphomas), 
lymphoblastic leukemia, melanoma, Ewing's sarcoma, primitive 
neuroectodermal tumor, rhabdomyosarcoma, neuroblastoma, 
medulloblastoma, undifferentiated carcinoma, blastic plasmacy-
toid dendritic cell neoplasm, extramedullary hematopoiesis (13) 
and small undifferentiated round cell tumors (6,14).
Previous studies have demonstrated that immunopheno-
type is of utmost importance in determining the diagnosis of 
GS (3-5). In particular, the literature has focused on the CD13 
and CD68 markers for granular monocytic and macrophagic 
cells, MPO and CD117 markers for myeloid differentiation, 
lysozyme marker for monocytic lineage, CD43 marker for 
myeloid cells as well as T cells and B precursors, and CD34 
and terminal deoxynucleotidyl transferase (TdT) markers 
for immature cells (10). Immunohistochemical detection of 
intracellular MPO, a major constituent of primary granules 
of neutrophilic myeloid cells, confirms a diagnosis of GS. 
However, while MPO is expressed in the majority of GSs, 
some minimally differentiated and monocytic GSs do not 
express it (8).
CD68-KP1 is the most commonly expressed marker, 
followed by MPO, CD117, CD99, CD68/PG M1, lysozyme, 
CD34, TdT, CD56, CD61/linker of activated T lympho-
cyte/factor VIII-related antigen, CD30, glycophorin A and 
CD4 (3). Rarely, aberrant antigenic expression is observed 
(such as cytokeratins, B- or T-cell markers) (3).
In the current case, immunohistochemical evaluation 
revealed strong reactivity for CD43, CD34 and CD99, whereas 
MPO was negative. In particular, the presence of CD99 made 
it difficult to differentiate GS from other CD99‑positive round 
cell tumors (14), whereas the positivity for CD34 (15) and the 
negativity for MPO indicated the presence of a mass of imma-
ture cells. In the present case, the clinical history of previous 
AML was the key to the specific diagnosis of GS.
From a therapeutic perspective, data from the literature 
suggest that GSs are extremely sensitive to focal irradiation or 
chemotherapy; however, their role is not well defined (13,16-28). 
The optimal treatment for the GS-AML association remains 
uncertain. However, high-dose chemotherapy and stem cell 
transplantation may be the treatment of choice (6).
The risk of metachronous AML in non-leukemic patients 
with GS is very high, with a median delay of 5 months; the 
majority of patients may develop AML within 1 year. There-
fore, early intensive (induction/intensification) chemotherapy 
similar to that used to treat AML must be administered, even 
in GS patients without AML upon initial diagnosis (6).
Byrd et al stated that 97% of all primary GS patients who 
did not receive systemic chemotherapy developed AML (12). 
Furthermore, 66% of patients who received chemotherapy 
for the primary GS did not develop AML, suggesting that 
early systemic therapy is helpful in preventing AML, which 
increases the overall survival time (6).
Literature data demonstrated that clinical behavior and 
response to therapy are not influenced by any of the following 
factors: Age, gender, anatomic site, de novo presentation, 
histotype, phenotype or cytogenetic findings (6).
In the current case, given the previous history of AML 
and according to data in the literature, the patient was treated 
with conventional induction AML therapy, followed by radio-
therapy. This choice, so far, has proved to be a successful 
strategy, since the patient has shown no signs of relapse after 
3-year follow-up.
In conclusion, the current study highlights certain inter-
esting features of GS. Firstly, the negative reactivity for MPO in 
the current case suggested the diagnosis of a poorly differenti-
ated GS with a poor prognosis. Thus, the patient was assigned 
to a multidisciplinary protocol of close follow-up for the high 
risk of relapse. Secondly, since the rhinopharynx is involved 
in a variety of malignant neoplasms, immunohistochemistry 
is required for the diagnosis of GS, particularly for the undif-
ferentiated forms, as in the present case. Indeed, it is not 
uncommon for GS to be misdiagnosed as lymphoma. Finally, a 
combination of detailed clinical, radiographic and serological 
work-ups, in association with a thorough histological assess-
ment, is essential to establish the correct diagnosis (29).
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